Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BSGM NASDAQ:LNSR NASDAQ:NEPH NASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSGMBiosig Technologies$4.45+8.3%$5.33$0.23▼$14.11$139.82M1.82705,424 shs1.25 million shsLNSRLENSAR$12.13-0.6%$12.79$3.80▼$17.31$144.77M0.49125,082 shs79,749 shsNEPHNephros$4.27-3.0%$3.81$1.36▼$5.00$45.27M1.2328,949 shs45,395 shsPDEXPro-Dex$35.70-1.9%$45.87$23.68▼$70.26$116.38M-0.0446,068 shs42,511 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSGMBiosig Technologies+5.93%-13.11%+9.60%-38.66%+817.62%LNSRLENSAR-1.13%-1.21%-5.21%-5.86%+159.57%NEPHNephros+11.96%+4.76%+12.82%+15.79%+134.04%PDEXPro-Dex+2.31%-20.96%-23.79%-12.86%+37.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSGMBiosig Technologies$4.45+8.3%$5.33$0.23▼$14.11$139.82M1.82705,424 shs1.25 million shsLNSRLENSAR$12.13-0.6%$12.79$3.80▼$17.31$144.77M0.49125,082 shs79,749 shsNEPHNephros$4.27-3.0%$3.81$1.36▼$5.00$45.27M1.2328,949 shs45,395 shsPDEXPro-Dex$35.70-1.9%$45.87$23.68▼$70.26$116.38M-0.0446,068 shs42,511 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSGMBiosig Technologies+5.93%-13.11%+9.60%-38.66%+817.62%LNSRLENSAR-1.13%-1.21%-5.21%-5.86%+159.57%NEPHNephros+11.96%+4.76%+12.82%+15.79%+134.04%PDEXPro-Dex+2.31%-20.96%-23.79%-12.86%+37.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSGMBiosig Technologies 3.00Buy$10.00124.72% UpsideLNSRLENSAR 2.00Hold$15.0023.66% UpsideNEPHNephros 3.00Buy$5.5028.81% UpsidePDEXPro-Dex 3.00Buy$56.0056.86% UpsideCurrent Analyst Ratings BreakdownLatest NEPH, BSGM, PDEX, and LNSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025NEPHNephrosMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.50 ➝ $6.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSGMBiosig Technologies$13K10,754.97N/AN/A($0.09) per share-49.44LNSRLENSAR$58.36M2.48N/AN/A$0.42 per share28.88NEPHNephros$16.68M2.71$0.02 per share196.39$0.81 per share5.27PDEXPro-Dex$66.59M1.75$3.15 per share11.34$11.23 per share3.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSGMBiosig Technologies-$10.33MN/A0.00N/AN/AN/A-5,336.99%-90.03%11/13/2025 (Estimated)LNSRLENSAR-$31.40M-$4.21N/A∞N/A-84.49%-737.30%-72.60%11/6/2025 (Estimated)NEPHNephros$70K$0.1235.58∞N/A7.95%14.89%11.64%11/6/2025 (Estimated)PDEXPro-Dex$8.98M$2.7013.2217.33N/A13.48%26.67%14.95%10/30/2025 (Estimated)Latest NEPH, BSGM, PDEX, and LNSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q4 2025PDEXPro-Dex$0.47$0.36-$0.11$0.36$17.90 million$17.49 million8/15/2025Q2 2025BSGMBiosig Technologies-$0.04-$0.74-$0.70-$0.74N/AN/A8/7/2025Q2 2025LNSRLENSAR-$0.0750-$0.15-$0.0750-$0.15$16.55 million$11.36 million8/7/2025Q2 2025NEPHNephros-$0.0250$0.02+$0.0450$0.02$3.60 million$4.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSGMBiosig TechnologiesN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSGMBiosig TechnologiesN/A0.030.03LNSRLENSARN/A1.520.88NEPHNephrosN/A5.414.14PDEXPro-Dex0.253.231.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSGMBiosig Technologies7.16%LNSRLENSAR40.15%NEPHNephros41.10%PDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipBSGMBiosig Technologies24.80%LNSRLENSAR66.00%NEPHNephros6.70%PDEXPro-Dex47.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSGMBiosig Technologies5031.42 million23.63 millionNo DataLNSRLENSAR11011.94 million4.06 millionOptionableNEPHNephros3010.60 million9.89 millionNot OptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableNEPH, BSGM, PDEX, and LNSR HeadlinesRecent News About These CompaniesPro-Dex, Inc. $PDEX Shares Sold by Punch & Associates Investment Management Inc.September 9 at 5:31 AM | marketbeat.comPro-Dex Full Year 2025 Earnings: EPS Misses ExpectationsSeptember 6, 2025 | finance.yahoo.comPro-Dex Reports Strong Fiscal 2025 Results Amid ChallengesSeptember 4, 2025 | tipranks.comPro-Dex, Inc. (PDEX) Lags Q4 Earnings and Revenue EstimatesSeptember 4, 2025 | zacks.comPro-Dex Revenue Jumps 16% in Fiscal Q4September 4, 2025 | aol.comAPro-Dex, Inc. Announces Fiscal 2025 Fourth Quarter and Full-Year ResultsSeptember 4, 2025 | accessnewswire.comAPro-Dex (PDEX) Expected to Announce Quarterly Earnings on ThursdayAugust 30, 2025 | marketbeat.comPro-Dex (NASDAQ:PDEX) Stock Price Passes Below 200 Day Moving Average - Should You Sell?August 28, 2025 | marketbeat.comHedge funds investors have a lot riding on Pro-Dex, Inc. (NASDAQ:PDEX) with 37% ownershipAugust 18, 2025 | uk.finance.yahoo.comPro-Dex (NASDAQ:PDEX) Cut to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comStrength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?July 29, 2025 | zacks.comPro-Dex, Inc. (PDEX) - Yahoo FinanceJuly 16, 2025 | finance.yahoo.comNew Strong Buy Stocks for July 1stJuly 1, 2025 | zacks.comBest Value Stocks to Buy for July 1stJuly 1, 2025 | zacks.comPro-Dex, Inc. (PDEX) Stock Price, Quote, News & Analysis - Seeking AlphaJune 27, 2025 | seekingalpha.comInvestors Shouldn't Overlook The Favourable Returns On Capital At Pro-Dex (NASDAQ:PDEX)June 23, 2025 | finance.yahoo.comHere is Why Growth Investors Should Buy ProDex (PDEX) NowJune 17, 2025 | zacks.comProDex (PDEX) Upgraded to Buy: Here's WhyJune 17, 2025 | zacks.comAre Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 20, 2025 | finance.yahoo.comPro-Dex: Crash After Strong Earnings Leads To A Buying OpportunityMay 5, 2025 | seekingalpha.comHere's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of InvestorsMay 4, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEPH, BSGM, PDEX, and LNSR Company DescriptionsBiosig Technologies NASDAQ:BSGM$4.45 +0.34 (+8.27%) Closing price 04:00 PM EasternExtended Trading$4.47 +0.02 (+0.56%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.LENSAR NASDAQ:LNSR$12.13 -0.07 (-0.57%) Closing price 04:00 PM EasternExtended Trading$12.12 -0.01 (-0.08%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Nephros NASDAQ:NEPH$4.29 -0.11 (-2.50%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Pro-Dex NASDAQ:PDEX$35.70 -0.69 (-1.90%) Closing price 04:00 PM EasternExtended Trading$35.56 -0.14 (-0.38%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Forget QQQ: This ETF Marries the Magnificent 7 and Communications Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
